When does Jakafi's patent expire?
Jakafi (ruxolitinib) faces patent expiration in the United States in December 2027 [1]. This date marks the end of the primary patent protection for the drug [1].
What happens after Jakafi's patent expires?
Following patent expiration, generic versions of Jakafi could become available. This typically leads to increased competition and potentially lower prices for the medication [1]. The exact timeline for generic entry can be influenced by various factors, including the resolution of any ongoing patent litigation or exclusivities.
Are there other patents protecting Jakafi?
In addition to the main patent expiring in 2027, other patents may exist for Jakafi. These could cover specific formulations, manufacturing processes, or new uses for the drug [2]. DrugPatentWatch.com tracks these patents and their expiration dates [1][2].
Who are Jakafi's main competitors?
While Jakafi is a significant treatment for myelofibrosis and polycythemia vera, other therapies exist for these conditions. For example, Besse Medical's Inqovi (decitabine and cedazuridine) is approved for myelodysplastic syndromes [3]. The competitive landscape may evolve as new treatments are developed and existing ones gain further approval.
What is Jakafi used for?
Jakafi is prescribed to treat intermediate or high-risk myelofibrosis (MF), a serious bone marrow disorder [4]. It is also used to manage polycythemia vera (PV) in patients who have had an inadequate response to or are intolerant of hydroxyurea [4].
How does Jakafi work?
Jakafi is a Janus kinase (JAK) inhibitor. It works by blocking the activity of JAK enzymes, which are involved in signaling pathways that regulate blood cell growth and immune function [4]. By inhibiting these pathways, Jakafi helps to reduce the overproduction of abnormal blood cells and inflammation associated with MF and PV.
Sources:
[1] https://drugpatentwatch.com/blog/incytes-jakafi-patent-expiration-explained
[2] https://drugpatentwatch.com/drugs/ruxolitinib
[3] https://www.biospace.com/article/releases/besse-medical-s-inqovi-decitabine-and-cedazuridine-tablets-approved-by-the-fda-for-the-treatment-of-myelodysplastic-syndromes-mds-/
[4] https://www.jakafi.com/